Hints and tips:
Related Special Reports
...make informed decisions about their healthcare, together with a medical professional”....
...He said its products complied with the EU’s “extremely strict” production standards and that its factories were comparable “to the Pfizers of the world”....
...Ogilvy, which has previously worked with a host of pharma groups including Pfizer and Johnson & Johnson, is launching a business that offers vetted influencers to talk about illnesses and possible solutions...
...Meanwhile, medical devices company Smith & Nephew wants to increase pay for its US executives to bring it closer to American levels....
...While some investors are sceptical of companies without long-term growth plans, she said Moderna had met every challenge....
...AstraZeneca’s vaccine has been superseded by jabs from BioNTech/Pfizer and Moderna, which were developed using mRNA technology and have become the most used worldwide....
...Its vaccine, a more traditional protein-based formulation combined with an adjuvant to boost its effectiveness, has been pitched to patients as a counterpoint to mRNA jabs from BioNTech/Pfizer and Moderna...
...This included a Merck agreement with Daiichi Sankyo worth up to $22bn, Pfizer’s $43bn acquisition of lossmaking Seagen and AbbVie’s $10.1bn acquisition of ImmunoGen....
...The US government arranged with Pfizer to return 7.9mn Paxlovid courses at the end of 2023, at an estimated cost to the company of $4.2bn....
...Vaccine hopes and demand for medical treatments also buoyed pharmaceutical groups such as Moderna and Pfizer in 2020, as well as lesser-known Chinese groups, including WuXi Biologics, Chongqing Zhifei Biological...
...The medical tourism component was “creative”, he added, emphasising that the key was to make “a live rhino worth more than a dead rhino”....
...It’s a drug that’s active against [resistant] pathogens that gives us a tool to treat the type of infection that we don’t have good options for now,” said Jay Purdy, Pfizer’s vice-president of global medical...
...A late-stage clinical trial using a different approach is now under way by Pfizer and Valneva, which is expected to report in 2025....
...GSK secured approval for Arexvy from the US Food and Drug Administration at the start of May, almost a month before Pfizer’s Abrysvo....
...Pfizer’s efforts to develop an obesity pill have suffered setbacks. It has abandoned plans for two treatments already....
...Pfizer is abandoning its plans for a weight loss pill to be taken twice a day after trials showed it caused significant side effects, in a setback to the US drugmaker’s effort to enter the fast-growing market...
...To make up for the shortfall in its pipeline, the US drugmaker earlier this year announced plans to buy Seagen, an oncology drugmaker, for $43bn; a deal Pfizer said it expected to close on Thursday....
...Doctors and patients groups have sounded an alarm over the rise in medical loans....
...There have been large investments in vaccine delivery systems in recent years, such as the mRNA technology used for the BioNTech/Pfizer and Moderna Covid-19 vaccines....
...Last week, Pfizer slashed its 2024 revenue outlook and increased its cost-cutting programme by $500mn....
...The US federal drug regulator has approved new Covid-19 boosters from Moderna and Pfizer, as it moves to contain infections from spreading more quickly in the US....
...BlackRock’s offices have also been targeted for periodic protests by climate activists who say it has not done enough to promote decarbonisation.In 2022, the asset manager set up personal security plans...
...In March, officials from 194 countries came together to agree on a global plan to deal with a threat known as “Disease X”....
...The Centers for Medicare & Medicaid Services said last month that Medicare Part D drug benefit plans will cover weight loss medicines when they are approved to treat a separate medical problem, such as heart...
...A consultation published on Monday included proposals to base eligibility for PIP on a formal medical diagnosis of someone’s condition rather than the current “functional” assessment of their ability to...
International Edition